哮喘管理的悖论:是时候采用新方法了吗?
该文指出哮喘维持治疗依从性差,症状加重时患者多增加短效β2受体激动剂(SABA)而非控制药物,归因于当前治疗方案的多个悖论。作者建议在GINA步骤1或2以吸入性糖皮质激素(ICS)与福莫特罗等速效支气管舒张剂组合替代SABA单药缓解治疗,但需大量临床数据才能获监管批准。
要点
- 哮喘维持治疗依从性差,症状加重时患者常增加SABA而非控制药物。
- 当前方案存在悖论,如GINA步骤1推荐SABA单药,尽管哮喘是慢性炎症性疾病。
- 建议GINA步骤1或2以ICS-福莫特罗等组合替代SABA单药缓解治疗。
核心结论
- 当前哮喘治疗approach存在多个悖论,导致患者早期过度依赖SABA。
- 建议以ICS与福莫特罗等速效支气管舒张剂组合替代SABA单药作为GINA步骤1或2的缓解治疗。
研究设计与样本
- 本文为综述/观点性文章,未报告系统检索范围或样本量。
主要发现
- 研究确认症状加重时多数患者增加SABA使用而非控制药物。
- GINA步骤1推荐SABA单药,尽管哮喘是慢性炎症性疾病。
- GINA步骤1患者有自主权且其需求和疾病控制感知被接受,但更高步骤推荐固定剂量方案而不顾症状严重程度。
- 上述悖论 unintended consequence 是建立早期过度依赖SABA的模式。
关键数值与推荐
- GINA步骤1推荐SABA支气管舒张剂单药使用。
- 更高哮喘治疗步骤推荐固定剂量方案, irrespective of symptom severity。
- 建议在GINA步骤1或2以ICS与福莫特罗或类似速效支气管舒张剂组合作为缓解治疗。
临床怎么用
- 临床应避免早期过度依赖SABA的模式。
- 可考虑患者调整治疗,即症状驱动使用缓解/控制组合药物。
- 以ICS-福莫特罗等组合替代SABA单药缓解治疗可确保早期更规律使用控制药物。
局限性
- 该新方法需大量临床数据才能获监管机构批准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Poor adherence to maintenance pharmacotherapy is a reality in asthma. Studies confirm that when symptoms worsen, most patients increase short-acting β2-agonist (SABA) use, instead of using controller medication. This behaviour might be attributable to several paradoxes in the current treatment approach. These paradoxes include the recommended use of a SABA bronchodilator alone at Global Initiative for Asthma (GINA) step 1, despite the fact that asthma is a chronic inflammatory disease. At step 1, the patient has autonomy and their perception of need and disease control is accepted, but at higher asthma treatment steps a fixed-dose approach is recommended, irrespective of symptom severity. The unintended consequence is the establishment of a pattern of early over-reliance on SABA. New approaches that avoid these paradoxes are needed, such as patient-adjusted therapy, in which patients adopt a symptom-driven approach using a combination reliever/controller. We propose that SABA reliever monotherapy should be replaced by a combination of inhaled corticosteroid (ICS) and formoterol, or similar rapid-onset bronchodilator, as reliever therapy for patients at GINA steps 1 or 2. This will ensure early and more regular administration of a controller medication. However, a significant body of clinical data will be needed before this approach can be approved by regulatory authorities.
引用
- O'Byrne PM, Jenkins C, Bateman ED, et al. The paradoxes of asthma management: time for a new approach? Eur Respir J. 2017. PMID: 28889114. doi:10.1183/13993003.01103-2017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。